As of December 31, 2022, Wave had $88.5 million in cash and cash equivalents, as compared to $150.6 million as of December 31, 2021. As previously disclosed, Wave entered into a strategic collaboration with GSK that became effective in the first quarter of 2023 and provided upfront cash of $170 million to Wave. Accordingly, the Company expects that its current cash and cash equivalents will be sufficient to fund operations into 2025.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on WVE:
- Wave Life Sciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
- Wave Life considers direct SVB exposure ‘immaterial’
- Wave Life Sciences to Webcast Conference Call of Fourth Quarter and Full Year 2022 Financial Results on March 22, 2023
- Wave Life Sciences to Present at the 2023 Virtual SVB Securities Global Biopharma Conference